In contrast to the methylation profile, the presence of well-described high molecular risk mutations in ASXL1, EZH2, IDH1/2, or SRSF2 is not able to predict progression to myelofibrosis (p = 0.99 in the multivariate analysis, see below). The gene discussed is EZH2; the disease is myelofibrosis.